Thư viện tập trung - Thư viện điện tử

Sách, tuyển tập

WHO Expert Committee on Specifications for Pharmaceutical Preparations [meeting held in Geneva from 10 to 15 December 1990] : thirty second report = Comité de Expertos de la OMS en Especificaciones para las Preparaciones Farmacéuticas : 32 informe, Ginebra, 10-15 de diciembre de 1990 / World Health Organization

Tác giả : World Health Organization

Nhà xuất bản : World Health Organization

Năm xuất bản : 1992

ISBN : 9241208236

Tùng thư : WHO technical report series

Chủ đề : 1. Drug Industry -- standards. 2. Pharmaceutical Preparations. 3. Quality Control.

Chia sẻ

Thông tin chi tiết

Tóm tắt :

Issues five sets of detailed guidelines intended to assist drug regulatory authorities in implementing a rigorous, comprehensive system for the quality control of pharmaceutical products. Focused on key components in a national system for quality assurance, the guidelines set out up-to-date principles, procedures, standards and requirements that can assist both regulators and manufacturers in their efforts to control the safety, quality, potency, and efficacy of pharmaceutical products The first and most extensive guidelines present updated requirements for good manufacturing practices in pharmaceutical production. The requirements, which are presented in three main parts, have been considerably revised and expanded from the 1975 version to reflect advances in pharmaceutical manufacturing technology. Part one outlines the general concepts and essential elements of quality assurance in the production of pharmaceuticals. The second part, on good practices in production and quality control, offers guidance on actions to be taken separately by production and by quality control personnel for the implementation of the general principles of quality assurance. The third part sets out supplementary guidelines for the manufacture of sterile preparations and the production of active pharmaceutical ingredients. The second guidelines provide a step-by-step description of the procedures to be followed during the inspection of pharmaceutical manufacturing facilities in order to ascertain adherence to good manufacturing practices. The third guidelines cover implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce, which has also been revised and considerably strengthened. To make the certification procedures better suited to rigorous control, particularly in view of the increasingly numerous reports of substandard and counterfeit drugs found on the market in developing countries, three different forms of attestation are proposed. Additional guidelines cover the quality of pharmaceutical and biological products prepared by recombinant DNA technology, and the validation of analytical procedures used in the examination of pharmaceutical products to ensure safety and efficacy at all stages of shelf-life, including storage, distribution and use. The remaining sections provide updated lists of available international chemical reference substances and of adopted international infrared reference spectra, and outline a protocol for a study on the quality of selected drugs at the point of use in developing countries Russian version of nos. 823 and 864 (partial translation) bound together (barcode no. 00073802 and 00073803)134 p.

Chia sẻ

Hiển thị MARC

Thông tin dữ liệu nguồn

Thư viện	Ký hiệu xếp giá	Dữ liệu nguồn
Tổ chức y tế thế giới		https://iris.who.int/handle/10665/39645

Ldr		00025nam a2200024 a 4500
001		CLN240811344
020	__	$a9241208236
041	__	$aen
041	__	$aja
041	__	$afr
041	__	$aru
041	__	$aes
100	__	$aWorld Health Organization
245	__	$aWHO Expert Committee on Specifications for Pharmaceutical Preparations [meeting held in Geneva from 10 to 15 December 1990] : thirty second report =$bComité de Expertos de la OMS en Especificaciones para las Preparaciones Farmacéuticas : 32 informe, Ginebra, 10-15 de diciembre de 1990 /$cWorld Health Organization
260	__	$bWorld Health Organization ,$c1992
490	__	$aWHO technical report series $v823
520	__	$aRussian version of nos. 823 and 864 (partial translation) bound together (barcode no. 00073802 and 00073803)134 p.
520	__	$aIssues five sets of detailed guidelines intended to assist drug regulatory authorities in implementing a rigorous, comprehensive system for the quality control of pharmaceutical products. Focused on key components in a national system for quality assurance, the guidelines set out up-to-date principles, procedures, standards and requirements that can assist both regulators and manufacturers in their efforts to control the safety, quality, potency, and efficacy of pharmaceutical products The first and most extensive guidelines present updated requirements for good manufacturing practices in pharmaceutical production. The requirements, which are presented in three main parts, have been considerably revised and expanded from the 1975 version to reflect advances in pharmaceutical manufacturing technology. Part one outlines the general concepts and essential elements of quality assurance in the production of pharmaceuticals. The second part, on good practices in production and quality control, offers guidance on actions to be taken separately by production and by quality control personnel for the implementation of the general principles of quality assurance. The third part sets out supplementary guidelines for the manufacture of sterile preparations and the production of active pharmaceutical ingredients. The second guidelines provide a step-by-step description of the procedures to be followed during the inspection of pharmaceutical manufacturing facilities in order to ascertain adherence to good manufacturing practices. The third guidelines cover implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce, which has also been revised and considerably strengthened. To make the certification procedures better suited to rigorous control, particularly in view of the increasingly numerous reports of substandard and counterfeit drugs found on the market in developing countries, three different forms of attestation are proposed. Additional guidelines cover the quality of pharmaceutical and biological products prepared by recombinant DNA technology, and the validation of analytical procedures used in the examination of pharmaceutical products to ensure safety and efficacy at all stages of shelf-life, including storage, distribution and use. The remaining sections provide updated lists of available international chemical reference substances and of adopted international infrared reference spectra, and outline a protocol for a study on the quality of selected drugs at the point of use in developing countries
650	_2	$aDrug Industry $xstandards
650	_2	$aPharmaceutical Preparations
650	_2	$aQuality Control
856	__	$uhttps://iris.who.int/handle/10665/39645
900		1
925		G
926		0
927		SH

Thông tin dữ liệu nguồn

Tài liệu cùng tác giả

WHO: Ebola situation report 14 October 2015 / World Health Organization

Seasonal influenza vaccine use in low and middle income countries in the tropics and subtropics: a systematic review / Hirve, Siddhivinayak;World Health Organization

WHO annual meeting with diagnostic manufacturers and stakeholders: global forecasts of diagnostic demand for 2014-2018, Geneva Switzerland / World Health Organization

Global antimicrobial resistance surveillance system: manual for early implementation / World Health Organization

WHO: Ebola situation report 7 October 2015 / World Health Organization

Lời ngỏ

Mục đích và phương châm hoạt động

Bản quyền